Pandemic Darlings The pandemic economy, in original documents
Home Court filings Public Health and Medical Professionals for Transparency v. Food and Drug Administration Joint status report — PHMPT v. FDA

Court filing

Joint status report — PHMPT v. FDA

Record facts

CourtU.S. District Court for the Northern District of Texas
Filed2023-03-24

U.S. District Court for the Northern District of Texas · No. 4:21-cv-01058-P · Doc. 67 · 2023-03-24 · Docket on CourtListener

Summary

A joint status report filed March 24, 2023 in Public Health and Medical Professionals for Transparency v. United States Food and Drug Administration, Civil Action No. 4:21-cv-01058-P, in the U.S. District Court for the Northern District of Texas, as Doc. 67. It reports FDA productions of 58,725 pages on January 3, 2023, 56,874 pages on February 1, 2023 and 13,492 pages on March 1, 2023, with 50,479 banked pages remaining and 779,206 pages produced to date. The plaintiff states that this exceeds the approximately 450,000 pages it had expected; the FDA responds that it complied with the court-ordered schedule. The FDA estimates approximately 372,000 pages remain and that production will be complete in November 2023. The parties say they will file another report within 90 days.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

IN THE UNITED STATES DISTRICT COURT 
FOR THE NORTHERN DISTRICT OF TEXAS 
 
) 
PUBLIC HEALTH AND MEDICAL 
) 
PROFESSIONALS FOR 
) 
TRANSPARENCY, 
) 
) 
Plaintiff, 
) 
) 
v. 
) 
Civil Action No. 4:21-cv-01058-P 
) 
UNITED STATES FOOD AND DRUG ) 
ADMINISTRATION, 
) 
) 
Defendant. 
) 
  
  ) 
 
 
JOINT STATUS REPORT 
 
Pursuant to the Court’s Order dated January 6, 2022 (Dkt. No. 35), the parties hereby submit 
the instant Joint Status Report (“JSR”). Consistent with this Court’s Order of February 2, 2022 (Dkt. 
No. 56), and in the interim since the parties’ last JSR, filed on December 24, 2022 (Dkt. No. 64), the 
U.S. Food and Drug Administration (“FDA”) has made the following additional productions: 
 A January 3, 2023 production consisting of 58,725 pages of responsive records;  
 A February 1, 2023 production consisting of 56,874 pages of responsive records; 
and 
 A March 1, 2023 production consisting of 13,492 pages of responsive records and 
FDA applied 41,508 of its banked pages to this production.  
 
 
 
Case 4:21-cv-01058-P   Document 67   Filed 03/24/23    Page 1 of 5   PageID 2287

 
 
Pursuant to the February 2, 2022 Order, FDA may “bank” any pages produced in excess of 
its monthly quota, and, if FDA is unable to produce the full amount of pages required in a subsequent 
month, it can apply the banked pages toward its quota for that month. To date, FDA has 50,479 
banked pages remaining. FDA expects to produce a minimum of 55,000 pages (or utilize its 
remaining banked pages to account for at least 55,000 pages) on or before April 3, 2023.  
On December 22, 2022, Plaintiff asked FDA to provide an estimated remaining page count 
and/or estimated completion date of production. On December 23, 2022, FDA responded that it was 
not presently in a position to provide an estimated remaining page count or estimated completion 
date because it was still assessing the scope of records incorporated into the Comirnaty biological 
product file, but that it expected to be better positioned to provide its best estimates at the time of 
the next joint status report. 
FDA has produced 779,206 pages to date.  
 Plaintiff’s Statement: Plaintiff asserts that this volume exceeds the volume of 
approximately 450,000 pages it had long expected. Hence, on September 27, 2022, 
Plaintiff wrote to  FDA about including in the then upcoming JSR “how many more 
pages of responsive documents the agency plans to produce,” to which FDA did not 
provide an estimate. Plaintiff again asked for an estimate on December 22, 2022, as 
noted above. FDA has now finally provided an estimate, which reflects a completion 
date well past that expected by Plaintiff. As for FDA’s claim below regarding what 
it advised in the earlier stages of this litigation related to estimated pages, the record 
speaks for itself. 
 Defendant’s Statement: FDA does not agree with Plaintiff’s characterization of 
their September 27, 2022 communications.  FDA acknowledges that the number of 
pages responsive to Plaintiff’s FOIA request exceeds the preliminary estimates 
Case 4:21-cv-01058-P   Document 67   Filed 03/24/23    Page 2 of 5   PageID 2288

 
 
provided by FDA at an earlier stage of the litigation but notes that, at the time, FDA 
made clear that there may be more responsive records than it had been able to account 
for thus far, including, inter alia, more unpaginated data files.  Additionally, FDA 
has complied with the Court-ordered production schedule in this matter.  At this time, 
FDA estimates that there are approximately 372,000 pages left to process.  Based on 
that estimate and the pages FDA has banked to date, FDA estimates that it will 
complete production of responsive records in November 2023.  FDA also notes that 
should it identify additional responsive records during the course of its continued 
review that would affect the anticipated completion date of November 2023, it will 
notify Plaintiff.  
The parties intend to continue discussing the remaining production and the volume and 
timing for completion of same. 
The parties will submit another joint status report within 90 days. 
 
 
 
Case 4:21-cv-01058-P   Document 67   Filed 03/24/23    Page 3 of 5   PageID 2289

 
 
Dated: March 24, 2023 
 
 
Respectfully submitted, 
 
SIRI & GLIMSTAD LLP 
 
/s/ Elizabeth A. Brehm__________ 
Aaron Siri, NY Bar No. 4321790  
Elizabeth A. Brehm, NY Bar No. 4660353 
200 Park Avenue 
    17th Floor 
New York, New York 10166 
Tel: (212) 532-1091 
aaron@sirillp.com  
ebrehm@sirillp.com    
 
Attorneys for Plaintiff 
 
BRIAN M. BOYNTON 
Principal Deputy Assistant 
Attorney General 
Civil Division 
 
ELIZABETH J. SHAPIRO 
   Deputy Director 
   Federal Programs Branch 
 
/s/ Kevin Wynosky 
 
KEVIN WYNOSKY 
   Trial Attorney 
United States Department of Justice 
Civil Division, Federal Programs 
Branch 
1100 L Street NW 
   Washington, D.C. 20005 
   Tel: (202) 616-8267 
   Email: kevin.j.wynosky@usdoj.gov 
 
Attorneys for Defendant 
 
 
 
Case 4:21-cv-01058-P   Document 67   Filed 03/24/23    Page 4 of 5   PageID 2290

 
 
CERTIFICATE OF SERVICE 
 
I hereby certify that on March 24, 2023, I electronically transmitted the foregoing to the 
parties and the clerk of court for the United States District Court for the Northern District of 
Texas using the CM/ECF filing system. 
 
/s/ Kevin Wynosky 
 
KEVIN WYNOSKY 
   Trial Attorney 
United States Department of Justice  
Civil Division, Federal Programs Branch 
 
 
Case 4:21-cv-01058-P   Document 67   Filed 03/24/23    Page 5 of 5   PageID 2291

File and source

File
gov.uscourts.txnd.353278.67.0.pdf
Size
138,124 bytes
SHA-256
eb50439416cb5c7dabafe3e211fdc73bf49e4671ad5ce22c19d4126d409225e6
Our copy
gov.uscourts.txnd.353278.67.0.pdf
Original
archive.org
Back to top